Anti-CD8 alpha antibody [EPR20305] (Ab209775)
CD8a, Lyt-2, Lyt2, Cd8a, T-cell surface glycoprotein CD8 alpha chain, T-cell surface glycoprotein Lyt-2
用户验证的应用
推荐稀释比例
- IHC-P1/2000 This antibody is not suitable for IHC immunofluorescent staining. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB1/1000
详细信息
背景信息
What is this antibody validated in? Anti-CD8 alpha antibody [EPR20305] (ab209775) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P) in Mouse samples. What is the molecular weight of CD8 alpha? Anti-CD8 alpha [EPR20305] (ab209775) specifically detects a band for CD8 alpha (UniProt: P01731) at a molecular weight of 27kDa. Trusted by the scientific community Anti-CD8 alpha [EPR20305] (ab209775) was first used in a scientific publication in 2017 and has been cited over 90 times in peer-reviewed journals. Reviewed by scientists Anti-CD8 alpha [EPR20305] (ab209775) has over 5 independent reviews from customers. Other related products We have a range of other formats of antibody clone [EPR20305] also available for your convenience: ab209775, Carrier free - ab228856, Alexa Fluor® 488 - ab313396 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (181)
Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer.
用 C 端 APC 的 11 个氨基酸肽靶向 PTPN13 可防止结直肠癌的免疫逃逸。
The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.
衰老微环境是胰腺癌免疫排斥和转移命运的决定因素。
Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma.
靶向富含亮氨酸重复激酶 2 可克服胶质母细胞瘤对溶瘤性单纯疱疹病毒疗法的耐药性。
FAPα(+) Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
FAPα(+)巨噬细胞通过PD-L1和T细胞衰老的双重调控，在多发性骨髓瘤中协调免疫逃逸。
CAR-T triggers TAM reeducation and adaptive anti-tumor response via TREM2 deficiency or CD40 agonist.
CAR-T 通过 TREM2 缺陷或 CD40 激动剂触发 TAM 再教育和适应性抗肿瘤反应。
Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.
信号素 6D 驱动抗肿瘤 I 型干扰素反应，从而重编程结直肠癌的肿瘤微环境。
Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer.
MicroRNA-29b 的缺失促进 DNMT3b 介导的 STING 下调，从而减弱 KRAS 突变型结直肠癌中放射治疗诱导的抗肿瘤免疫。
Smaller Oxygen Nanobubbles More Effectively Suppress Colitis and Colon Carcinogenesis than Larger Oxygen Nanobubbles.
较小的氧纳米气泡比大的氧纳米气泡更能有效地抑制结肠炎和结肠癌的发生。
Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer.
前列腺癌疫苗与免疫检查点抑制剂联合使用可产生协同作用，从而消除前列腺癌。
Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy.
硫柳汞通过直接作用抑制肿瘤恶性进展，并增强基于 PD-1 的免疫疗法的疗效。
- 1
- 2
- 3
- 4
- 5
- 6
- 19